Health Care/Hospital
Rznomics Presents Clinical Interim Data for RZ-001 in Recurrent Glioblastoma at ASNO 2026
* Dr. Chae-Yong Kim of Seoul National University Bundang Hospital delivers oral presentation on interim data from 10 enrolled patients * A manageable safety profile, with prolonged disease control and tumor recurrence inhibition observed in several patients SEONGNAM and SEOUL, South Korea, Ju...
2026-06-15 12:00
7206
Harbour BioMed Secures Landmark Victory in U.S. Patent Infringement Case Against Amgen, Reshaping the Global Antibody Patent Landscape
* The case, originally filed in 2021 by Harbour Antibodies, asserted that Amgen and Teneobio (an Amgen subsidiary) infringed patents protecting Harbour's groundbreaking antibody discovery platform * Delaware jury finds infringement willful and patent valid, and awards full $20.2 million in da...
2026-06-15 08:01
6651
Global Heart Hub finds women delay seeking heart care by continuing to put others first
* Heart symptoms continue to be dismissed or mistaken for other conditions, such as anxiety, new global patient-led research reveals. * Findings were presented at the European Society of Cardiology's ACNAP Congress 2026, organised by the Association of Cardiovascular Nursing & Allied Professi...
2026-06-13 00:30
4563
Simcere Pharmaceutical Enters into a Research Collaboration Agreement with Stanford Medicine to Develop Innovative Therapies for Patients with Idiopathic Pulmonary Fibrosis
SHANGHAI, June 12, 2026 /PRNewswire/ -- On May 29, 2026, Pacific Time, Simcere Pharmaceutical Group Limited (2096.HK) entered into a research collaboration agreement with Stanford Medicine to jointly advance an exploratory study in the respiratory field, with the aim of developing innovative ther...
2026-06-12 14:59
8037
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
HONG KONG, June 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab(AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-s...
2026-06-12 09:57
8095
Harbour BioMed Appoints Dr. Dhavalkumar Patel as Scientific Advisor
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 11, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-06-12 09:19
8834
Peer-reviewed publication shows that Lateral pharma's SCP drugs for neuropathic pain act via the novel target LanCL1
MELBOURNE, Australia, June 11, 2026 /PRNewswire/ -- Lateral Pharma today announced the publication of peer-reviewed research in PAIN, a leading journal dedicated to pain research, identifying Lanthionine Synthetase C-Like Protein 1 (LanCL1) as a novel therapeutic target for neuropathic pain. The ...
2026-06-11 16:22
6392
CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights
SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O) backbone therapy. I. Trispecific Design Rationale and Di...
2026-06-11 14:20
7287
Caliway Unveils Latest OI25 Animal Study Data for CBL-514 in Combination with GLP-1R-Based Weight-Loss Therapies at ADA 2026, Demonstrating Dual Potential to Attenuate Post-Discontinuation Weight Regain and Improve Metabolic Health
Backed by International Authority — Caliway's latest preclinical data on its proprietary localized fat reduction candidate, CBL-514, in combination with GLP–1R–based weight–loss therapies, were presented at the American Diabetes Association 2026 Scientific Sessions (ADA 2026). The findings were d...
2026-06-11 12:54
5005
Elixiron Immunotherapeutics Reports Positive Phase 2 Interim Results for Enrupatinib: Evidence of Neuroinflammation Reduction and Early Cognitive Benefit in Alzheimer's Disease
CAMBRIDGE, Mass. and TAIPEI, June 10, 2026 /PRNewswire/ -- Elixiron Immunotherapeutics (TPEx: 7871), a clinical-stage biopharmaceutical company pioneering precision immunotherapy for neurodegenerative and autoimmune diseases, today announced positive interim results from its ongoing Phase 2 proo...
2026-06-11 10:56
8683
Harbour BioMed Appoints Dr. Luisa Salter-Cid as Scientific Advisor
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-06-11 09:52
4469
MINISH USA Showcases Pioneering Minimally Invasive Dental Innovations at CDA Presents 2026 in Anaheim
LOS ANGELES, June 10, 2026 /PRNewswire/ -- MINISH USA, a rising global leader in advanced medtech and biomimetic tooth restoration, announced today its highly successful return to the California Dental Association's (CDA) flagship annual meeting. Held from May 14 to 16 at the Anaheim Convention C...
2026-06-10 23:00
5760
HkeyBio Launches "NHP Fast-PoC" Program to Deliver Low-Cost Cyno PK/PD and Developability Data Amid Rising NHP Prices
The cost-effective platform delivers rapid pharmacological validation data in cynomolgus monkeys, helping biotech firms make confident R&D decisions before committing to full-scale IND studies. BOSTON and SUZHOU, China, June 10, 2026 /PRNewswire/ -- HkeyBio, a specialized preclinical CRO focused...
2026-06-10 21:16
7720
QingSong Health Corp (2661.HK) and Basel Medical Sign Strategic Cooperation Memorandum to Explore AI Healthcare Services in Southeast Asia
BEIJING, June 10, 2026 /PRNewswire/ -- Recently, QingSong Health Corp (2661.HK) andBasel Medical Group Ltd announced the signing of a Memorandum of Strategic Cooperation. The two parties intend to explore cooperation in AI-enabled healthcare services, insurance-related healthcare solutions, and c...
2026-06-10 21:05
7996
Vatech Completes Full-Portfolio EU MDR Certification
Certification covers all three dental imaging categories and every 2026 model launch HWASEONG, South Korea, June 10, 2026 /PRNewswire/ -- Vatech (KOSDAQ: 043150), a global leader in dental imaging, today announced the completion of EU Medical Device Regulation (MDR; Regulation (EU) 2017/745) cer...
2026-06-10 21:00
5336
UndoAge and Novonesis Forge Strategic Partnership to Drive High-Quality Development of China's Probiotic Industry
Beijing, June 10, 2026 /PRNewswire/ -- UndoAge and Novonesis, a global biosolutions company backed by Novo Holdings, signed a Memorandum of Understanding (MOU) in Beijingon June 9. The partnership will deepen collaboration in probiotics and microbiome health, with a focus on high-growth consumer...
2026-06-10 20:38
4057
Alteogen Showcases ALT-B4's Potential to Transform ADC Development at World ADC Summit 2026
Preclinical data demonstrate enhanced systemic exposure and bioavailability, reduced dermal toxicity, and improved safety profile in ALT-B4-enabled ADC therapy Key Points * Superior PK: Subcutaneous administration of ADCs combined with ALT-B4 demonstrated rapid absorption, enhanced systemic e...
2026-06-10 17:00
6986
Harbour BioMed Announces NMPA Acceptance of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, June 10, 2026 /PRNewswire/ -- Harbour BioMed (the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology, oncology and other disease areas, today an...
2026-06-10 12:06
6004
First Patients Dosed in Phase 2 SIRIUS COPD Study of HBM9378/WIN378, a Fully Human Ultra Long-Acting Anti-TSLP Antibody
* COPD study initiation expands HBM9378/WIN378 (also known as SKB378) development into a second major respiratory disease * HBM9378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026 * HBM9378/WIN378 has th...
2026-06-09 20:23
6042
SK bioscience Joins Forces with Global Institutions to Advance Rotavirus Vaccine Development
* SK bioscience licenses vaccine technology from the U.S. Centers for Disease Control and Prevention * SK bioscience is jointly investing with the RIGHT Foundation to drive process development that enhances both efficacy and productivity * "We are committed to improving public health through...
2026-06-09 20:00
3704
Week's Top Stories
Most Reposted
Carro secures strategic investment from Orico
[Picked up by 295 media titles]
2026-09-18 16:29CityUHK and University of Cambridge establish Centre for Advanced and Smart Manufacturing to shape Hong Kong's Industry 5.0 future
[Picked up by 291 media titles]
2026-09-22 18:37
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
[Picked up by 281 media titles]
2026-09-17 13:09
CGS International Convenes China-ASEAN Business Leaders Summit to Deepen Capital Connectivity Across the Corridor
[Picked up by 277 media titles]
2026-09-23 09:00
01F Group Announces Investment in DANA, Indonesia's Leading Digital Financial Company, Reinforcing Long-Term Confidence in Asia's Fintech Opportunity
[Picked up by 275 media titles]
2026-09-21 08:00Most Read
COSRX Brings Its 5 Peptide Lip Collection to Ulta Beauty Stores Offline
2026-09-18 22:00
11421
Avnet and The University of Hong Kong Open EMUS Lab to Accelerate AI Innovation and Commercialization in Hong Kong
2026-09-17 13:09
10617
Ohmyhome Limited Regains Compliance with Nasdaq Minimum Closing Bid Price Rule
2026-09-17 20:00
8856
American Savings Bank Jumps More Than 6% in Trading Debut: NYSE Content Update
2026-09-17 21:21
8389
Sea, Gardens, Lawns and Hearths: Life Abroad Across Noah's N+ Club Network
2026-09-18 23:04
8138